Stockscreener 앱 받기
5.07
5.41%
0.26
시간 외 거래:
5.04
-0.03
-0.59%
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Market Fear: Whats the profit margin of CytomX Therapeutics IncWeekly Stock Recap & Precise Swing Trade Alerts - baoquankhu1.vn
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 - Bitget
Kynam Capital files 5.29% stake in CytomX (NASDAQ: CTMX) - Stock Titan
CytomX Therapeutics Target of Unusually High Options Trading (NASDAQ:CTMX) - MarketBeat
CytomX Therapeutics, Inc. to Announce Full Year 2025 Financial Results on March 16, 2026 - Quiver Quantitative
Biotech CytomX sets Mar. 16 call on 2025 financial results - Stock Titan
CTMX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CytomX Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
CytomX Therapeutics, Inc. (CTMX): Investor Outlook Reveals 55.71% Potential Upside - DirectorsTalk Interviews
CTMXCytomx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Earnings Recap: Is CytomX Therapeutics Inc a good ESG investment2025 Stock Rankings & Proven Capital Preservation Methods - baoquankhu1.vn
CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Is CytomX Therapeutics Inc stock showing strong momentumJuly 2025 Sector Moves & Low Risk High Reward Ideas - baoquankhu1.vn
Will CytomX Therapeutics Inc. (6C1) stock rise with strong economyWeekly Trend Recap & Smart Swing Trading Techniques - mfd.ru
Unmasking CytomXA Pioneer In Masked Therapeutics - RTTNews
Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating - Finviz
Tang Capital reports 0% CytomX (CTMX) stake in latest 13G/A filing - Stock Titan
Is CytomX Therapeutics Inc. stock positioned well for digital economyDip Buying & Real-Time Buy Signal Notifications - mfd.ru
CTMX Should I Buy - Intellectia AI
Is CytomX Therapeutics Inc. (6C1) stock a fit for income portfolios2025 Buyback Activity & Expert Curated Trade Setups - mfd.ru
Will CytomX Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Big Picture & Entry Point Strategy Guides - mfd.ru
Can CytomX Therapeutics Inc. disrupt its industryEarnings Recap Summary & Fast Entry Momentum Alerts - mfd.ru
Market Trends: What hedge funds are buying CytomX Therapeutics Inc2025 Fundamental Recap & AI Enhanced Trading Signals - baoquankhu1.vn
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Recap: Is CytomX Therapeutics Inc benefiting from interest rate changesMarket Sentiment Report & Technical Pattern Based Buy Signals - baoquankhu1.vn
CytomX Therapeutics, Inc. (CTMX) Investor Outlook: A Biotech Pioneer with a 61.87% Potential Upside - DirectorsTalk Interviews
CytomX Therapeutics Conference: CFO Highlights Varseta-M CRC Response Data, Next Catalysts - MarketBeat
FMR LLC's Strategic Acquisition of CytomX Therapeutics Inc Shares - GuruFocus
CytomX at Guggenheim Summit: Promising CRC Treatment Path By Investing.com - Investing.com Canada
Stock Recap: Is CytomX Therapeutics Inc benefiting from interest rate changes2025 Institutional Moves & Capital Protection Trade Alerts - baoquankhu1.vn
How New Analyst Assumptions Are Rewriting The Story For CytomX Therapeutics (CTMX) - Yahoo Finance
CTMX: Masked ADC shows 28% response in late-line CRC; registrational study planned by 2027 - TradingView
Rally Mode: Can CytomX Therapeutics Inc navigate macro headwindsJuly 2025 PreEarnings & High Yield Equity Trading Tips - baoquankhu1.vn
CytomX Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX) - The Globe and Mail
Analysts bullish ahead of colorectal cancer readout for CytomX Therapeutics, Inc. (CTMX) - MSN
CytomX Therapeutics, Inc. (CTMX) Investor Outlook: Exploring a 58.73% Potential Upside Amid Innovative Oncology Developments - DirectorsTalk Interviews
Analysis Recap: Whats the profit margin of CytomX Therapeutics IncWeekly Trend Summary & Smart Investment Allocation Tips - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Will CytomX Therapeutics Inc. (6C1) stock outperform foreign stocksJuly 2025 News Drivers & AI Enhanced Trade Execution Alerts - mfd.ru
CytomX Therapeutics (CTMX) Price Target Increased by 20.20% to 8.67 - Nasdaq
Cantor Fitzgerald Raises Price Target for CytomX Therapeutics (C - GuruFocus
Cantor Fitzgerald Raises CytomX Therapeutics (NASDAQ:CTMX) Price Target to $10.00 - MarketBeat
CTMX: Barclays Analyst Raises Price Target to $10.00 | CTMX Stock News - GuruFocus
CytomX Therapeutics to Present at Upcoming February Conferences - 富途牛牛
CytomX Therapeutics price target raised to $10 from $8 at Barclays - TipRanks
A Look At CytomX Therapeutics (CTMX) Valuation After Optimistic Analyst Target Hikes On Phase 1 Cancer Data - Sahm
CytomX Therapeutics stock hits 52-week high at 6.16 USD By Investing.com - Investing.com Nigeria
CytomX Therapeutics (NASDAQ:CTMX) Hits New 1-Year HighHere's Why - MarketBeat
CytomX Therapeutics stock hits 52-week high at 6.16 USD - Investing.com
CytomX Therapeutics (CTMX) Is Up 14.0% After Early Probody Colorectal Cancer Data Are Welcomed By Analysts – Has The Bull Case Changed? - Yahoo Finance
Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) - Insider Monkey
0.11%
6.00%
자본화:
|
볼륨(24시간):